Innovation Driving Opportunities For Active Transdermal Drug Delivery Analysis By Greystone Associates Reveals Market And Technology Factors
With compliance concerns continuing to drive investment in new drug delivery technologies, interest in transdermal delivery systems is proliferating. But as work with passive transdermal systems has progressed, so too has the realization of the true extent of the barrier to drug delivery presented by the stratum corneum, the skin’s outer layer of dead cells.
More: continued here
Filed under: Dermatology on January 29th, 2008